生物技术公司Sarepta Therapeutics（SRPT）今日盘中股价大涨5.31%，引发市场关注。截至发稿，该股报价38.35美元/股，成交量80.6861万股，换手率0.82%。
尽管Sarepta Therapeutics最近的财报显示公司净亏损4.48亿美元，每股亏损4.60美元，但机构投资者对该公司仍保持积极态度。在参与评级的25家机构中，80%给予买入建议，20%给予持有建议，无券商给予卖出建议。这种积极的机构评级可能是推动股价上涨的因素之一。
值得注意的是，高盛近期维持了对Sarepta Therapeutics的"买入"评级，但将目标价从178.00美元下调至100.00美元。尽管目标价有所下调，但高盛仍然看好该公司的长期发展前景，这可能为投资者提供了信心，推动了股价的上涨。Sarepta Therapeutics作为一家专注于治疗罕见疾病的生物技术公司，其创新的RNA靶向技术平台和广泛的产品管线可能继续吸引投资者的关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.